Latest news with #TrapitBansal
Economic Times
15 hours ago
- Health
- Economic Times
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
What's Behind the FDA's New Warning? Who Faces the Highest Risk? Live Events What's Changing in the Vaccine Labels? What's the FDA Doing Next? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update:"Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
Time of India
15 hours ago
- Health
- Time of India
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a report. What's Behind the FDA's New Warning? These warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the report. ALSO READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Who Faces the Highest Risk? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business report. ALSO READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? Live Events What's Changing in the Vaccine Labels? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update: "Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the report. The label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business report. ALSO READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming What's the FDA Doing Next? While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the report. The agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business report. FAQs Why is the FDA updating warnings now? The FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business report. Are Moderna and Pfizer vaccines still considered safe? Yes, the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
Time of India
16 hours ago
- Business
- Time of India
Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI?
Meta has poached Trapit Bansal, a key AI researcher from OpenAI who contributed significantly to their early AI reasoning and reinforcement learning efforts. Bansal's move to Meta's new AI superintelligence team underscores the intense competition for AI talent. This team aims to develop next-generation AI reasoning models, rivaling those of OpenAI and Google. Tired of too many ads? Remove Ads Ex-OpenAI Researcher Trapit Bansal Joins Meta A Key Figure in OpenAI's Reasoning Work Tired of too many ads? Remove Ads Joining a Powerhouse Team at Meta Mark Zuckerberg's AI Hiring Spree Tired of too many ads? Remove Ads FAQs Meta has made another bold move in the AI talent wars by hiring Trapit Bansal , an AI researcher who played a pivotal role in shaping OpenAI 's early efforts in AI reasoning and reinforcement learning, according to a report by who joined OpenAI in 2022, is now among the most publicly visible names to leave the firm and join Meta's brand-new AI superintelligence team , an initiative that's fast attracting all the top minds in the field of AI, as per the spokesperson Kayla Wood confirmed the news to TechCrunch that Bansal had departed OpenAI, while even Bansal's LinkedIn page mentions that he has left OpenAI in June this year, according to the TechCrunch READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? During his time at OpenAI, Bansal worked closely with co-founder Ilya Sutskever and played an instrumental role in the development of the company's foundational AI reasoning model, o1, as reported by growing interest in AI reasoning models , especially as Meta's competitors like OpenAI's o3 and DeepSeek's R1 hit new performance milestones, makes Bansal's move even more impactful, according to the READ: Karoline Leavitt says no enriched uranium was removed from Iranian nuclear sites prior to US attacks Bansal brings his expertise to an impressive team at Meta's AI superintelligence lab, which includes former Scale AI CEO Alexandr Wang, ex-Google DeepMind researcher Jack Rae, and machine learning veteran Johan Schalkwyk, as per the report. Bloomberg and The Wall Street Journal reported that several other former OpenAI researchers, Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai, have recently joined Meta as mission of the lab is to develop next-gen AI reasoning models that may match or exceed OpenAI and Google, however, Meta has not yet put out a public AI reasoning model, as reported by READ: Last chance to claim your Fortnite refund – Act fast or risk missing out on free cash Meta CEO Mark Zuckerberg has also been making compensation deals in the $100 million range to lure top AI talent to build his new AI team, as reported by TechCrunch. However, it is not known what Bansal was offered to join in this deal, as reported by has also reportedly tried to acquire startups with heavy-hitting AI research labs, like Sutskever's Safe Superintelligence, Mira Murati's Thinking Machines Labs, and Perplexity, to further fill out its new AI unit, but those talks never progressed to a final stage, according to the a recent podcast, OpenAI CEO Sam Altman asserted that Meta has been trying to poach his startup's top talent, but highlighted that 'none of our best people have decided to take him up on that,' quoted an AI researcher who helped OpenAI develop its first major reasoning model and worked closely with Ilya a newly formed unit aimed at developing advanced AI reasoning models, similar to those at OpenAI and Google.
&w=3840&q=100)
Business Standard
18 hours ago
- Business
- Business Standard
Meta recruits leading OpenAI researcher Trapit Bansal for AI reasoning lab
Meta has onboarded a prominent OpenAI researcher, Trapit Bansal, to work on advanced aritificial intelligence (AI) reasoning models within its recently established AI superintelligence team, according to a report by TechCrunch. Trapit Bansal had been with OpenAI since 2022 and played a major role in launching the company's reinforcement learning research, working closely with co-founder Ilya Sutskever. He is named as one of the original contributors to OpenAI's first AI reasoning model, known as o1. His LinkedIn profile indicates that he left OpenAI in June. OpenAI spokesperson Kayla Wood confirmed to TechCrunch that Bansal had indeed exited the organisation. Boost to Meta's AI superintelligence team Bansal is expected to significantly strengthen Meta's new AI superintelligence group, which already includes notable figures such as former Scale AI CEO Alexandr Wang. The team is also in discussions to bring in former GitHub CEO Nat Friedman and Safe Superintelligence co-founder Daniel Gross. His expertise could help Meta develop a cutting-edge AI reasoning model to compete with leading offerings like OpenAI's o3 and DeepSeek's R1. At present, Meta does not have a publicly available AI reasoning model. Zuckerberg's high-profile hiring strategy In recent months, Meta CEO Mark Zuckerberg has aggressively recruited top AI talent, reportedly offering compensation packages as high as $100 million. While Bansal's offer remains undisclosed, his decision to join indicates the success of Zuckerberg's strategy in attracting leading AI researchers. According to The Wall Street Journal, Bansal will join other recent hires from OpenAI — Lucas Beyer, Alexander Kolesnikov, and Xiaohua Zhai — at Meta. The team also includes Jack Rae, formerly of Google DeepMind, and Johan Schalkwyk, previously with startup Sesame, according to a Bloomberg report. Attempts to acquire AI startups fell through In a bid to expand its AI capabilities further, Meta also explored acquiring startups known for their AI research, including Safe Superintelligence (co-founded by Sutskever), Mira Murati's Thinking Machines Labs, and Perplexity. However, none of these talks reached a final agreement. On a recent podcast, OpenAI CEO Sam Altman commented on Meta's recruitment attempts, stating, 'None of our best people have decided to take him up on that.' AI reasoning a critical focus for Meta Developing powerful AI reasoning models is essential for Meta's new unit. Over the past year, firms such as OpenAI, Google, and DeepSeek have released high-performing models that can tackle complex tasks by reasoning through problems before producing answers. This approach, which makes use of additional computation time and resources, has led to improved performance both in benchmarks and in real-world applications. Future ambitions for Meta's AI lab Meta's AI superintelligence group is expected to become a crucial part of its wider operations, similar to the role DeepMind plays within Google. The company has plans to develop AI agents for enterprise use, led by Clara Shih, the former Salesforce CEO of AI.
Yahoo
19 hours ago
- Business
- Yahoo
Meta hires key OpenAI researcher to work on AI reasoning models
Meta has hired a highly influential OpenAI researcher, Trapit Bansal, to work on its AI reasoning models under the company's new AI superintelligence unit, a person familiar with the matter tells TechCrunch. OpenAI spokesperson Kayla Wood confirmed to TechCrunch that Bansal had departed OpenAI. Bansal's LinkedIn page says that he left OpenAI in June. Bansal has worked at OpenAI since 2022 and was a key player in kickstarting OpenAI's work on reinforcement learning alongside OpenAI co-founder Ilya Sutskever. Bansal is listed as a foundational contributor on OpenAI's first AI reasoning model, o1. Bansal could offer a significant lift to Meta's AI superintelligence lab, which also features leaders such as former Scale AI CEO Alexandr Wang, former GitHub CEO Nat Friedman, and Safe Superintelligence co-founder Daniel Gross. Meta currently does not publicly offer an AI reasoning model as part of its Llama family of open models. In recent months, Mark Zuckerberg has been on a hiring spree to build out Meta's new AI team, offering $100 million compensation packages to top researchers who join his company. It's unclear what Bansal was offered to join in this deal. A Meta spokesperson declined to comment. This is a developing story. Check back for updates…
